Clinical trials
ctDNA clinical trials
Below are recruiting ctdna clinical trials, each written for real people, not researchers. We’re tracking 186 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05708235RecruitingPhase 2
Using blood test results to guide breast cancer treatment
This Phase 2 study tests whether doctors can use a blood test (ctDNA) to find breast cancer recurrence risk early and guide further treatment. Depending on your ctDNA result and tumor markers, you may receive standard hormone therapy or one of several additional treatment options.
A CoruñaAges 18 years+ - NCT05715229RecruitingPhase 2
Blood test–guided treatment choice for advanced lung cancer
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Washington D.C., District of ColumbiaAges 18 years+ - NCT05787197Recruiting
Blood test to guide treatment after colon cancer liver surgery
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
BesançonAges 18 years+ - NCT05797077RecruitingPhase 3
After-surgery blood test–guided therapy for colon cancer liver spread
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
Guangzhou, GuangdongAges 18–75 - NCT05802407Recruiting
ctDNA blood test monitoring after pancreatic cancer surgery
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
BeijingAges 18 years+ - NCT05802394Recruiting
Using blood tests to track cancer after pancreatic treatment
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
BeijingAges 18 years+ - NCT05815082RecruitingPhase 3
ctDNA-guided chemo after liver surgery for colon cancer
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
Guangzhou, GuangdongAges 18–75 - NCT05837260Recruiting
Tracking tumor DNA changes in advanced thyroid cancers
This study looks at a small blood test (called ctDNA) and tumor tissue to understand how advanced thyroid cancers change over time. It may help doctors better monitor cancer growth and guide treatment choices.
LondonAges 18 years+ - NCT05916755Recruiting
Testing tumor clues that predict response to immunotherapy
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
BarcelonaAges 18 years+ - NCT05917106Recruiting
Testifying methylomics blood test for new kidney cancer monitoring
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Nanjing, JiangsuAges Any age - NCT05940311Recruiting
Blood test for melanoma with BRAF V600E mutation
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
RomeAges 18 years+ - NCT05947838Recruiting
Blood test helps choose chemotherapy before colorectal or appendix surgery
This study uses a blood test called ctDNA to help tailor (personalize) neoadjuvant chemotherapy for people with colorectal or appendix cancer before surgery. The goal is to see if using ctDNA can help doctors pick the most appropriate chemotherapy plan for you.
Houston, TexasAges 18 years+ - NCT05965024Recruiting
Using ctDNA blood tests to predict lung cancer return after surgery
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05965479RecruitingPhase 2
Blood test to guide extra stomach or esophagus cancer treatment
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Guildford, SurreyAges 18 years+ - NCT06050694RecruitingPhase 2
Testing glofitamab plus chemo for untreated DLBCL
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Toronto, OntarioAges 18 years+ - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT06071286Recruiting
Study tracking DNA from tumors in advanced ovarian cancer
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
RomaAges 18–80 - NCT06087120Recruiting
Can a blood test predict breast cancer treatment response?
This study looks at whether a blood test (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. It focuses on people with HER2-positive or triple-negative breast cancer that has not spread far.
JakartaAges 18 years+ - NCT06088381RecruitingPhase 2
HPV-related throat cancer treatment based on tumor DNA levels
This trial tests if monitoring cancer DNA left in your blood after surgery can help decide if you need additional treatment. It is for people with HPV-positive oropharynx (throat) cancer who have a certain amount of cancer DNA detected before surgery.
Baltimore, MarylandAges 18 years+ - NCT06105177Recruiting
Using blood tests to guide lung cancer care
This trial uses a simple blood test (liquid biopsy) to find tumor DNA in people suspected of having lung cancer. The goal is to learn if this test can help doctors make better treatment decisions without needing a tissue sample.
Heerlen, LimburgAges 18 years+ - NCT06111105Recruiting
Comparing blood tests to guide colon cancer treatment
This study compares different blood tests to find the best way to detect tiny bits of cancer DNA after surgery for stage III colorectal cancer. It aims to help doctors decide if additional chemotherapy is needed to prevent the cancer from coming back.
Graz, StyriaAges 18 years+ - NCT06167967Recruiting
Blood test for chemotherapy guidance in stage 3 colorectal cancer
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
Hanzhou, ZhejiangAges 18–75 - NCT06198868Recruiting
MRD blood test to guide treatment in lung cancer
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Nanjing, JiangsuAges 18 years+ - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+
Hear when a new ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ctdna?
- Yes. Clin2 currently lists 186 recruiting ctdna studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ctdna trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ctdna trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.